Skip to main content

Yesterday, Dec. 3, 2015, 104 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $196.39 to $17,869,068.00.

Highlighted Stocks Traded by Insiders:

Amphastar Pharmaceuticals (AMPH) - FREE Research Report

Applied Physics & Chemistry Laboratories, Inc., who is 10% Owner at Amphastar Pharmaceuticals, sold 38,583 shares at $15.45 on Dec. 3, 2015. Following this transaction, the 10% Owner owned 7.6 million shares meaning that the stake was reduced by 0.51% with the 38,583-share transaction.

The shares most recently traded at $15.00, down $0.45, or 3.02% since the insider transaction. Historical insider transactions for Amphastar Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,772
  • 12-Week # shares sold: 3,772
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 10,772

The average volume for Amphastar Pharmaceuticals has been 244,800 shares per day over the past 30 days. Amphastar Pharmaceuticals has a market cap of $691.5 million and is part of the health care sector and drugs industry. Shares are up 32.3% year-to-date as of the close of trading on Thursday.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. Currently, there are 4 analysts who rate Amphastar Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMPH - FREE

TheStreet Quant Ratings

rates Amphastar Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins. Get the full

TheStreet Recommends

Amphastar Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CBRE Group (CBG) - FREE Research Report

Frese Calvin W Jr, who is CEO, Americas at CBRE Group, sold 25,000 shares at $37.50 on Dec. 3, 2015. Following this transaction, the CEO, Americas owned 280,042 shares meaning that the stake was reduced by 8.2% with the 25,000-share transaction.

The shares most recently traded at $36.57, down $0.93, or 2.54% since the insider transaction. Historical insider transactions for CBRE Group go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 83,000
  • 24-Week # shares sold: 158,540

The average volume for CBRE Group has been 2.3 million shares per day over the past 30 days. CBRE Group has a market cap of $12.3 billion and is part of the financial sector and real estate industry. Shares are up 5.05% year-to-date as of the close of trading on Thursday.

CBRE Group, Inc. operates as a commercial real estate services and investment company worldwide. The company operates through Americas; Europe, Middle East and Africa; Asia Pacific; Global Investment Management; and Development Services segments. The company has a P/E ratio of 21.7. Currently, there are 5 analysts who rate CBRE Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBG - FREE

TheStreet Quant Ratings

rates CBRE Group as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

CBRE Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

First Merchants (FRME) - FREE Research Report

Sherman Patrick A, who is Director at First Merchants, bought 18 shares at $27.36 on Dec. 3, 2015. Following this transaction, the Director owned 29,858 shares meaning that the stake was boosted by 0.06% with the 18-share transaction.

Lehman Gary, who is Director at First Merchants, bought 61 shares at $27.36 on Dec. 3, 2015. Following this transaction, the Director owned 25,216 shares meaning that the stake was boosted by 0.24% with the 61-share transaction.

The shares most recently traded at $26.94, down $0.42, or 1.56% since the insider transaction. Historical insider transactions for First Merchants go as follows:

  • 4-Week # shares bought: 81
  • 4-Week # shares sold: 1,600
  • 12-Week # shares bought: 227
  • 12-Week # shares sold: 1,600
  • 24-Week # shares bought: 641
  • 24-Week # shares sold: 1,600

The average volume for First Merchants has been 132,600 shares per day over the past 30 days. First Merchants has a market cap of $1.0 billion and is part of the financial sector and banking industry. Shares are up 16.88% year-to-date as of the close of trading on Thursday.

First Merchants Corporation operates as the financial holding company for First Merchants Bank, National Association that provides community banking services. The stock currently has a dividend yield of 1.64%. The company has a P/E ratio of 15.3. Currently, there is 1 analyst who rates First Merchants a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRME - FREE

TheStreet Quant Ratings

rates First Merchants as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, attractive valuation levels and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

First Merchants Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.